Recent News

• 05.13.2026 - Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
• 05.07.2026 - Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
• 05.04.2026 - Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
• 04.27.2026 - Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
• 03.25.2026 - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Recent Filings

• 05.13.2026 - 8-K Current report
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 8-K Current report
• 04.28.2026 - 3 Initial statement of beneficial ownership of securities
• 04.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.27.2026 - DEF 14A Other definitive proxy statements
• 04.27.2026 - 8-K Current report